Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea

키워드

참고문헌 (47)

1. McNamara LM, "Perspective on post-menopausal osteoporosis : establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures", J R Soc Interface, 7, pp.353~372 (2010)[DOI]
2. "Healthcare bigdata hub: Disease subdivision statistics 2019-2021" (2022)[URL]
3. Lips P, "Quality of life as outcome in the treatment of osteoporosis : the development of a questionnaire for quality of life by the European Foundation for Osteoporosis", Osteoporos Int, 7, pp.36~38 (1997)[DOI]
4. Lips P, "Quality of life in patients with osteoporosis", Osteoporos Int, 16, pp.447~455 (2005)[DOI]
5. 안승희, "Osteoporosis and Osteoporotic Fracture Fact Sheet in Korea", 대한골대사학회지, 27(4), pp.281~290 (2020), 대한골대사학회
6. 유준일, "Incidence and Mortality of Osteoporotic Refractures in Korea according to Nationwide Claims Data", Yonsei Medical Journal, 60(10), pp.969~975 (2019), 연세대학교의과대학[DOI]
7. Policy brief for osteoporosis management in super-aged society, "Korean Society for Bone Mineral Research", Korean Society for Bone Mineral Research, ~ (2020)
8. Jackson M, "Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among women in South Korea : a simulation projection model from 2020 to 2040", Arch Osteoporos, 16, pp.115~ (2021)[DOI]
9. Cummings SR, "Denosumab for prevention of fractures in postmenopausal women with osteoporosis", N Engl J Med, 361, pp.756~765 (2009)[DOI]
10. Bone HG, "10 years of denosumab treatment in postmenopausal women with osteoporosis : results from the phase 3 randomised FREEDOM trial and open-label extension", Lancet Diabetes Endocrinol, 5, pp.513~523 (2017)[DOI]
11. "Amgen 'Prolia®', Expanding health insurance coverage as first-line therapy for osteoporosis" (2019)[URL]
12. "Prolia dominates the osteoporosis drug market" (2021)[URL]
13. Jönsson B, "Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis", Osteoporos Int, 22, pp.967~982 (2011)[DOI]
14. Sonnenberg FA, "Markov models in medical decision making : a practical guide", Med Decis Making, 13, pp.322~338 (1993)[DOI]
15. Edejer TT, "Making choices in health: WHO guide to cost-effectiveness analysis", World Health Organization, ~ (2003)
16. 배그린, "폐경기 골다공증 환자에서 데노수맙 사용에 대한 비용-효과 분석", 한국임상약학회지, 28(2), pp.131~137 (2018), 한국임상약학회[DOI]
17. Chau D, "Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada", J Med Econ, 15(Suppl 1), pp.3~14 (2012)[DOI]
18. Trends in osteoporosis treatment and incidence of osteoporotic fracture in Korea, "Noh SH", National Health Insurance Service Ilsan Hospital, ~ (2021)
19. 장선미, "골다공증 환자의 의료이용 양상", Endocrinology and Metabolism, 25(4), pp.326~339 (2010), 대한내분비학회
20. Lee YK, "Mortality after vertebral fracture in Korea : analysis of the National Claim Registry", Osteoporos Int, 23, pp.1859~1865 (2012)[DOI]
21. 윤현구, "Incidence and Mortality Following Hip Fracture in Korea", Journal of Korean Medical Science, 26(8), pp.1087~1092 (2011), 대한의학회
22. Barrett JA, "Mortality and pulmonary embolism after fracture in the elderly", Osteoporos Int, 14, pp.889~894 (2003)[DOI]
23. Kanis JA, "The burden of osteoporotic fractures : a method for setting intervention thresholds", Osteoporos Int, 12, pp.417~427 (2001)[DOI]
24. Kanis JA, "The cost-effectiveness of alendronate in the management of osteoporosis", Bone, 42, pp.4~15 (2008)[DOI]
25. "Foreign exchange rate" (2022)[URL]
26. Health Insurance Review & Assessment Service, "Pharmaceutical economic evaluation guidelines", Health Insurance Review & Assessment Service, ~ (2021)
27. "Healthcare bigdata hub: Disease classification (stage 3) statistics" (2021)[URL]
28. Health Insurance Review & Assessment Service, "Fee-for-service price 2020", Health Insurance Review & Assessment Service, ~ (2020)
29. Status report of healthcare coverage, "National Health Insurance Service", National Health Insurance Service, ~ (2019)
30. Korean National Health Insurance Service, "Drug reimbursement price ceiling table", Korean National Health Insurance Service, ~ (2021)
31. Korean National Health Insurance Service, "Weighted-average drug price table", Korean National Health Insurance Service, ~ (2021)
32. "Consumer price index" (2020)[URL]
33. Barrionuevo P, "Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women : A network meta-analysis", J Clin Endocrinol Metab, 104, pp.1623~1630 (2019)[DOI]
34. Freemantle N, "Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments : a meta-analysis", Osteoporos Int, 24, pp.209~217 (2013)[DOI]
35. Li L, "Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database", Menopause, 19, pp.33~40 (2012)[DOI]
36. Mori T, "Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan", Osteoporos Int, 28, pp.1733~1744 (2017)[DOI]
37. Hiligsmann M, "Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium", Pharmacoeconomics, 29, pp.895~911 (2011)[DOI]
38. Karnon J, "What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia", Cost EffResour Alloc, 14, pp.11~ (2016)[DOI]
39. Parthan A, "Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US", Appl Health Econ Health Policy, 11, pp.485~497 (2013)[DOI]
40. Ström O, "Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis", Osteoporos Int, 24, pp.1491~1502 (2013)[DOI]
41. Park JH, "Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis", BMC Musculoskelet Disord, 18, pp.152~ (2017)[DOI]
42. Imaz I, "Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk : systematic review and meta-analysis", Osteoporos Int, 21, pp.1943~1951 (2010)[DOI]
43. "Fosamax tab (Alendronate sodium)" (2008)[URL]
44. "Prolia® Pre-filled syringe (Denosumab)" (2014)[URL]
45. Mosca L, "Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease", Stroke, 40, pp.147~155 (2009)[DOI]
46. Biju Benjamin, "Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis", Osteoporosis and Sarcopenia, 2(2), pp.77~81 (2016), 대한골다공증학회[DOI]
47. Lyu H, "Comparison of denosumab and bisphosphonates in patients with osteoporosis : A meta-analysis of randomized controlled trials", J Clin Endocrinol Metab, 104, pp.1753~1765 (2019)[DOI]

관련 논문AI추천